Jump to content
Sclero Forums

Search the Community

Showing results for tags 'pulmonary fibrosis'.



More search options

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • Worldwide
    • Welcome: Guidelines and FAQs
    • Sclero Forums (MAIN)
    • UK Scleroderma
    • News
    • Personal Support

Blogs

  • CFM Babs from Chorley FM
  • barefut impressions
  • My Two Cents...
  • Amanda Thorpe's Blog
  • Joelf's Blog
  • Michael Thorpe's Blog

Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

Joined

  • Start

    End


Group


Location

Found 17 results

  1. Short–term progression of interstitial lung disease (ILD) in systemic sclerosis (SSc) predicts long–term survival in two independent clinical trial cohorts. These findings suggest that short–term changes in surrogate measures of SSc–ILD progression may have important effects on long–term outcomes. PubMed, Ann rheumatologist Dis, 11/08/2018. (Also see Pulmonary Fibrosis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  2. Recent progress in systemic sclerosis–interstitial lung disease (SSc–ILD). The implications of much of this ongoing work is our ability to identify those patients at risk for progression, and to offer novel therapies that can limit the progression of inflammatory and fibrotic lung disease. PubMed, Curr Opin Rheumatol, 2018 Nov;30(6):570-575. (Also see Pulmonary Fibrosis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  3. Prediction of therapeutic response before and during I.v. cyclophosphamide (IVCY) pulse therapy for interstitial lung disease in systemic sclerosis (SSc–ILD): A longitudinal observational study. ILD severity/activity before treatment and variability of serum Krebs von den Lungen-6, surfactant protein D levels during treatment may be useful to predict therapeutic effects of IVCY on SSc–ILD. PubMed, J Dermatol, 10/05/2018. (Also see Pulmonary Fibrosis Treatments) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  4. Radiological images of interstitial pneumonia in mixed connective tissue disease (MCTD) compared with scleroderma (SSc) and polymyositis/dermatomyositis(PM/DM). HRCT images in MCTD patients can be classified as SSc pattern or PM/DM pattern. PubMed, Eur J Radiol, 2018 Oct;107:26-32. (Also see Correlation between Pulmonary Fibrosis and other Diseases, Mixed Connective Tissue Disease and Dermatomyositis and Polymyositis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  5. TLR4-dependent fibroblast activation drives persistent organ fibrosis in skin and lung. The results suggest that systemic scleroderma patients with high TLR4 activity might show optimal therapeutic response to selective inhibitors of MD2/TLR4 complex formation. PubMed, JCI Insight, 2018 Jul 12;3(13). (Also see Fibroblasts, Skin Fibrosis and Pulmonary Fibrosis Research) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  6. Association of serum homocysteine level and lung involvement in systemic sclerosis (SSc). It seems that the serum level of homocystein has a minor role in the lung involvement of SSc patients or its effects are modified by other factors. PubMed, Curr Rheumatol Rev, 06/28/2018. (Also see Pulmonary Fibrosis Disease Correlations) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  7. CT Features of the Usual Interstitial Pneumonia (UIP) Pattern: Differentiating Connective Tissue Disease–Associated Interstitial Lung Disease (CTD–ILD) From Idiopathic Pulmonary Fibrosis (IPF). Although UIP is usually associated with IPF, the index of suspicion for CTD-ILD should be raised in the care of patients with any of the three CT signs. PubMed, AJR Am J Roentgenol, 2018 Feb;210(2):307-313. (Also see Correlation between Pulmonary Fibrosis and other Diseases) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  8. Factors associated with the 6–minute walk distance (6MWD) in patients with systemic sclerosis (SSc). During SSc, the 6MWD is independently associated with initial HR and HR variation; suggesting that pulmonary vasculopathy may have a greater impact than parenchymal involvement on functional limitation. PubMed, Arthritis Res Ther, 2017 Dec 15;19(1):279. (Also see Pulmonary Fibrosis Diagnosis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  9. Cyclophosphamide for connective tissue disease–associated interstitial lung disease. Researchers may consider comparing cyclophosphamide versus antifibrotic agents, or comparing both versus placebo, in particular, for those with evidence of rapidly progressive fibrotic disease, who may benefit the most. PubMed, Cochrane Database Syst Rev, 01/03/2018. (Also see Treatments for Pulmonary Fibrosis: Oral and IV Cyclophosphamide) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  10. CCL2 in the Circulation Predicts Long-Term Progression of Interstitial Lung Disease (ILD) in Patients With Early Systemic Sclerosis (SSc). Higher CCL2 levels in the circulation were predictive of ILD progression and poorer survival in patients with early SSc, which support the notion that CCL2 has a role as a biomarker and potential therapeutic target. PubMed, Arthritis Rheumatol, 2017 Sep;69(9):1871-1878. (Also see Pulmonary Fibrosis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  11. The status of pulmonary fibrosis in systemic sclerosis is associated with IRF5, STAT4, IRAK1, and CTGF polymorphisms. The analysis revealed that gene variation in four genes – IRF5, STAT4, CTGF and IRAK1 – was linked to lung fibrosis in scleroderma. PubMed, Rheumatol Int, 04/22/2017. (Also see Pulmonary Fibrosis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  12. Pulmonary Artery (PA) Dimensions as a Prognosticator of Transplant–Free Survival in Scleroderma Interstitial Lung Disease (SSc–ILD). In SSc–ILD patients, a PA:ascending aorta (Ao) ratio ≥1.1 is associated with higher risk of lung transplant or death. PubMed, Lung, 04/29/2017. (Also see Pulmonary Fibrosis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  13. Th–17 cytokines and interstitial lung involvement in systemic sclerosis (SSc). In diffuse SSc patients our results show a clear link between Th–17 cytokines measured both in exhaled breath condensate and in serum with interstitial lung involvement. PubMed, J Breath Re, 2016 Nov 21;10(4):046013. (Also see Cytokines and Pulmonary Fibrosis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  14. M10, a caspase cleavage product of the hepatocyte growth factor receptor, interacts with Smad2 and demonstrates antifibrotic properties in vitro and in vivo. M10 peptide interacts with Smad2 and demonstrates strong antifibrotic effects in vitro and in vivo in an animal model of lung fibrosis and should be considered as a potential therapeutic agent for systemic sclerosis and other fibrosing diseases. PubMed, Transl Res, 2016 Apr;170:99-111. (Also see Skin Fibrosis and Pulmonary Fibrosis) This item was posted in the ISN Newsroom Please check the newsroom daily for updates on scleroderma and other related articles.
  15. Netrin–1 Regulates Fibrocyte Accumulation in the Decellularized Fibrotic Sclerodermatous Lung Microenvironment and in Bleomycin–Induced Pulmonary Fibrosis. Netrin–1 regulates bleomycin–induced pulmonary fibrosis in mice and it might be a novel therapeutic target in scleroderma–related interstitial lung disease. PubMed, Arthritis Rheumatol, 2016 May;68(5):1251-61. (Also see Pulmonary Fibrosis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  16. Research of Lung Fibrosis in Scleroderma (SSc) Reveals High Levels of Antibodies That Correlate with Disease Progression. Circulating antibodies against specific chemokine receptors exist in higher levels in patients with SSc and these antibodies correlate with disease progression and clinical manifestations of the disease. Scleroderma News, 02/25/2016. (Also see Pulmonary Fibrosis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  17. Does anyone here suffer from crackling sounds from the lungs when breathing? I can hear it plain as day when I lay down. My scleroderma doctor can hear them, but my general practitioner could not. I had a pulmonary function test and my lungs don't have the same capacity as they use to. Also on X-Ray, it shows up as fibrosis. Last night the sound was very loud, I called Healthlink here in Alberta Canada, it’s a service where registered nurses take your symptoms and determine whether of not you should see a doctor. Today they just said monitor it. Last night it really scared me because the sound was really bad. Any other people with these symptoms?
×
×
  • Create New...